BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19950957)

  • 1. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
    Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
    J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.
    Simard JR; Getlik M; Grütter C; Schneider R; Wulfert S; Rauh D
    J Am Chem Soc; 2010 Mar; 132(12):4152-60. PubMed ID: 20201574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.
    Gill A; Cleasby A; Jhoti H
    Chembiochem; 2005 Mar; 6(3):506-12. PubMed ID: 15696598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
    Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
    Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
    Simard JR; Rauh D
    Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
    Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
    Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.
    Michelotti EL; Moffett KK; Nguyen D; Kelly MJ; Shetty R; Chai X; Northrop K; Namboodiri V; Campbell B; Flynn GA; Fujimoto T; Hollinger FP; Bukhtiyarova M; Springman EB; Karpusas M
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5274-9. PubMed ID: 16169718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations.
    Simard JR; Rauh D
    Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
    Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
    J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
    Ahn YM; Clare M; Ensinger CL; Hood MM; Lord JW; Lu WP; Miller DF; Patt WC; Smith BD; Vogeti L; Kaufman MD; Petillo PA; Wise SC; Abendroth J; Chun L; Clark R; Feese M; Kim H; Stewart L; Flynn DL
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5793-8. PubMed ID: 20800479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
    Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JX401, A p38alpha inhibitor containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast.
    Friedmann Y; Shriki A; Bennett ER; Golos S; Diskin R; Marbach I; Bengal E; Engelberg D
    Mol Pharmacol; 2006 Oct; 70(4):1395-405. PubMed ID: 16847144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.
    Meyers MJ; Pelc M; Kamtekar S; Day J; Poda GI; Hall MK; Michener ML; Reitz BA; Mathis KJ; Pierce BS; Parikh MD; Mischke DA; Long SA; Parlow JJ; Anderson DR; Thorarensen A
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1543-7. PubMed ID: 20137931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors.
    Chen J; Zhang Z; Stebbins JL; Zhang X; Hoffman R; Moore A; Pellecchia M
    ACS Chem Biol; 2007 May; 2(5):329-36. PubMed ID: 17465519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.